 |
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a...
Hashtag.net.au
Look at the Range of Dental Care Available Choosing a dental practice is easier when patients can access different types of care in one place. A dental clinic Melbourne patients visit may provide gen...
Hashtag.net.au
In clinical settings, surgical supply partners aren’t just vendors. They sit quietly behind the scenes of operating lists, specialist consultations, treatment rooms and recovery workflows. When they...
Hashtag.net.au
The early developmental years of a child's life represent a critical window for neurological growth, behavioural shaping, and language acquisition. During this formative phase, the ability to interpre...